Study on metabolomics of Xiaoqinglong Decoction Granules in the treatment of chronic persistent cold syndrome of bronchial asthma
Objective To evaluate the clinical efficacy of Xiaoqinglong Decoction Granules in the treatment of chronic persistent cold syndrome of bronchial asthma;To explore its treatment mechanism.Methods A randomized double-blind controlled study was performed.Totally 60 patients from the Respiratory Department of Guang'anmen Hospital,Chinese Academy of Traditional Chinese Medicine from January 2021 to January 2022 were selected as the observation subjects.They were divided into two groups using a random number table method,with 30 cases in each group.The control group was given conventional treatment plus placebo,and the experimental group was given conventional treatment plus Xiaoqinglong Decoction Granules.The treatment for both group lasted for 14d.TCM syndromes and clinical symptoms before and after treatment were scored.Asthma Control Test Questionnaire(ACT)was used to evaluate asthma control status,and the Asthma Quality of Life Questionnaire(Mini AQLQ)was used to evaluate the physiological and psychological effects of asthma on patients;FEV1 was detected using a German Jaeger lung function instrument FEV1/FVC.A exhaled nitric oxide(FeNO)detection instrument was used to observe the changes in FeNO at a flow rate of 50 ml/s,and non-targeted metabolomics analysis was performed using liquid chromatography-mass spectrometry(LC-MS);adverse reactions were observed during treatment and drug safety was evaluated.Results Eventually 47 cases were included,24 cases of test group and of 23 cases of control group.Xiaoqinglong Decoction Granules could reduce the TCM syndrome score of patients with chronic duration cold syndrome of asthma(P＜0.05).2 weeks after treatment,follow up for 4 weeks experimental group clinical symptom score[3.00(1.00,4.00),3.00(0.00,4.00)vs.3.5(3.00,5.00),Z=8.62],breathing symptom scores[1.00(0.00,1.00),1.00(0.00,1.00)vs.1.00(0.75,2.00),Z=6.80],cough symptom score[0.50(0.00,1.00),1.00(0.00,1.00)vs.1.00(0.00,1.25),Z=6.12]were lower than those in the experimental group before treatment in the same group(P＜0.01 or P＜0.05).The ACT score of the experimental group at 4 weeks of follow-up was[22.50(21.00,24.00)vs.9.00(15.00,21.50),Z=-4.87],Mini AQLQ score(78.5±12.46 vs.71.27±9.70,t=-2.46)and the control group had an ACT score of[24.00(19.00,25.00)vs.21.5(8.00,23.00)Z=-3.18]at 4 weeks of follow-up was higher than before treatment in the same group(P＜0.01 or P＜0.05).The experimental group was followed up for 4 weeks with a FEV1 of[2.96(2.27,3.49)L vs.2.60(2.32,3.49)L,Z=-3.72],FEV1/FVC[(80.83±6.84)％vs.(77.46±8.15)％,t=-2.32]and FeNO[24.00(12.50,31.00)ppb vs.30.00(17.00,91.00)ppb,Z=-3.72]was higher than before treatment in the same group(P＜0.01 or P＜0.05).Through LC-MS technique analysis,there were 75 kinds of different metabolites between the experimental group before and after treatment,and 295 kinds of different metabolites between the control group and the experimental group after treatment.Further intersection of differential metabolites showed that they were mainly concentrated in histidine metabolic pathway,phosphonate metabolic pathway and phosphate metabolic pathway.Related metabolites 2-aminoethyl phosphonate and thiomalonic acid were involved.Conclusions Xiaoqinglong Decoction Granules can effectively improve the TCM syndrome and clinical symptoms of patients with chronic persistent cold syndrome of asthma,especially for wheezing,cough and chest tightness,which can improve the levels of FEV1 and FEV1/FVC in patients and effectively reduce FeNO.Through metabolomics studies,it is speculated that Xiaoqinglong Decoction Granules may play a role in the treatment of asthma by regulating histidine metabolism pathway through thiomalonic acid.
AsthmaBronchiStatus asthmaticusXiao Qing Long TangMetabolomicsRandomized controlled study
万方数据
